Has Moustafa Sabri, MD received payments from drug or device companies?

Yes. Drug and device makers reported $690 in general payments to Moustafa Sabri, MD across 29 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Moustafa Sabri, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Moustafa Sabri, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Moustafa Sabri, MD

Interventional Cardiology · Park Ridge, ILNPI 1831112234

Payments from drug & device makers

$690in general payments, 2019–2025

Across 29 payments — averaging $23.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$544
E.r. Squibb & Sons, L.L.C.$43
Abbott$37
Johnson & Johnson$37
Kiniksa Pharmaceuticals International, PLC$29

What the payments were for

Food & beverage$690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	22	$544
E.r. Squibb & Sons, L.L.C.	2	$43
Abbott	2	$37
Johnson & Johnson	2	$37
Kiniksa Pharmaceuticals International, PLC	1	$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Farapulse$124
VIGILANT X4 CRT-D$121

How this compares

$690 in reported general payments places this provider in the 10th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois →

Medicare billing

Part B allowed, 2024

$203,023

Medicare patients

871

Services billed

2,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	338	$447,537
EntrestoSacubitril/Valsartan	74	$114,870
XareltoRivaroxaban	81	$102,708
MultaqDronedarone Hcl	14	$32,183
VascepaIcosapent Ethyl	39	$25,453
JardianceEmpagliflozin	23	$25,173
Metoprolol Succinate	492	$8,588
Atorvastatin Calcium	658	$6,729
Rosuvastatin Calcium	355	$5,867
Carvedilol	531	$5,070
Ezetimibe	174	$4,025
Losartan Potassium	300	$3,003
Amlodipine Besylate	330	$2,647
Omega-3 Acid Ethyl Esters	27	$2,552
Valsartan	77	$1,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonXarelto	$37	$102,70881 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Park Ridge

Neal SawlaniPark Ridge$587K
Adib ChausPark Ridge$81K
Charles DavidsonChicago$5.8M
Ravi RamanaPalos Park$2.8M
Mark RicciardiEvanston$2.2M
Andrei PopElk Grove Village$1.9M
Krishna Rocha SinghSpringfield$1.7M
Bruce LewisMaywood$1.3M
Justin LevisayEvanston$837K
Atman ShahChicago$794K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →